Sandhoff Disease is a rare genetic disorder. It affects the brain and nerves. It's caused by a missing enzyme called hexosaminidase A and B. This leads to a buildup of a fatty substance called GM2 ganglioside in nerve cells. It's similar to Tay-Sachs disease but usually starts later in life.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Sandhoff disease is a rare inherited disorder that gradually destroys nerve cells in the brain and spinal cord. It belongs to a group of conditions called lysosomal storage disorders, in which a missing enzyme lets a fatty substance build up inside cells until it damages them. In Sandhoff disease that substance is mainly GM2 ganglioside, and the damage shows up as a steady loss of movement, senses and thinking. The most common form begins in infancy. Babies usually seem to develop normally until about 3 to 6 months of age, then their progress slows and they start losing skills they had gained, such as rolling over, sitting and crawling. Many react with an exaggerated startle to loud noises. Seizures, vision and hearing loss and intellectual disability follow as the disease advances. Unlike the closely related Tay-Sachs disease, Sandhoff disease can also affect other organs, sometimes enlarging the liver, spleen or heart and causing bone changes. Juvenile and adult forms are much rarer and progress more slowly. The juvenile form starts between ages 2 and 10 with speech difficulties, clumsiness, seizures and declining thinking skills. In adults, the main problems are usually weakness in the legs, hips and arms, poor balance and numbness from nerve damage, sometimes with psychiatric or memory changes.
Sandhoff disease is caused by variants in the HEXB gene. This gene helps make two enzymes, beta-hexosaminidase A and B, that break down certain fats and sugars inside cells. When both enzymes work poorly, GM2 ganglioside and related substances accumulate, especially in nerve cells. How much enzyme activity remains largely determines the form: almost none leads to the infantile form, while a small amount of remaining activity is linked to later onset and slower progression. The condition is autosomal recessive, meaning a person has it only when both copies of HEXB carry variants. Parents who each carry one altered copy usually have no symptoms. When both parents are carriers, each pregnancy has a 25% chance of a child with Sandhoff disease, a 50% chance of a child who is a carrier, and a 25% chance of a child with two working copies. Sandhoff disease occurs in all populations but is more common in a few communities, including the Creole population of northern Argentina, Métis people in Saskatchewan, Canada, and people of Lebanese ancestry. Nothing a parent did or did not do causes it.
In an infant, the pattern of lost milestones, exaggerated startle and low muscle tone often leads a doctor to suspect a storage disorder. An eye exam may show a cherry-red spot, a characteristic mark at the back of the eye seen in Sandhoff and Tay-Sachs disease. Brain imaging can show changes that support the suspicion but cannot confirm the diagnosis on its own. The key test measures the activity of the beta-hexosaminidase enzymes, usually in a blood sample. In Sandhoff disease, both hexosaminidase A and hexosaminidase B are low or absent. This distinguishes it from Tay-Sachs disease, where only hexosaminidase A is low. Genetic testing of the HEXB gene then confirms the diagnosis, identifies the specific variants, and makes carrier testing of relatives and testing in future pregnancies possible. The later-onset forms are often missed for years because weakness, unsteady walking and nerve damage can resemble more common neurological conditions. In one study of late-onset GM2 disorders (the group that includes Sandhoff and Tay-Sachs disease), people saw an average of eight healthcare providers before getting the diagnosis. When these symptoms have no clear explanation, asking whether hexosaminidase testing has been done can shorten that search.
There is no cure for Sandhoff disease and no approved treatment that slows the disease itself. Care focuses on comfort, function and preventing complications, and it works best when a team coordinates it, often including a neurologist, a metabolic or genetics specialist, and therapists. Seizures are treated with anti-seizure medicines, though they can become harder to control over time. Feeding and swallowing support matters a great deal: as swallowing weakens, food or liquid can go into the airway and cause pneumonia, so many children eventually need a feeding tube to get enough nutrition and fluids safely. Keeping the airway clear and treating chest infections promptly help protect breathing. Physical, occupational and speech therapy, along with mobility and communication aids, support people with the later-onset forms in staying active and independent for as long as possible. For infants, palliative care teams (specialists focused on comfort and quality of life, alongside other care) can help families plan for comfort and make decisions as needs change. Research is active but early. A small, uncontrolled trial of gene therapy, which delivers working copies of the hexosaminidase genes into the brain, raised enzyme levels that peaked within weeks and were declining by about six months. Even so, infants in the trial showed a period of clinical stabilization: they kept feeding safely by mouth for longer, and their seizures started later and were milder. Older children developed worsening involuntary muscle contractions (dystonia), which led to their exclusion from further enrollment. Oral medicines, including N-acetyl-L-leucine (a modified amino acid) and nizubaglustat (a drug that reduces production of the fatty substances that build up in this disease), have shown possible short-term benefits in small studies of older children and adults. Neither is approved for Sandhoff disease, and clinical trials are the main way to receive them for this condition. Families can ask the care team whether any trial fits.
The course depends heavily on the form. In the infantile form, decline continues over months to a few years. Children gradually lose the ability to move, see, hear and swallow, and most do not survive past early childhood, often because of breathing infections. Care at home typically involves feeding support, seizure management and a growing amount of hands-on help, and many families rely on home nursing, respite care and palliative care services. The juvenile and adult forms progress much more slowly, over years to decades, and vary widely from person to person. Walking, balance and speech usually become harder over time, and many people come to rely on mobility aids and help with daily activities. Regular follow-up with a neurologist and therapists helps track changes and adjust support. Caring for someone with Sandhoff disease is demanding, and caregivers often describe the physical, emotional and financial strain as constant. Patient organizations for Tay-Sachs and related disorders offer information, connection with other families and help finding clinical trials.
See a clinician if a baby who was developing normally stops making progress or starts losing skills such as rolling over or sitting, or if an older child or adult develops unexplained, worsening weakness, unsteadiness or numbness. If Sandhoff disease runs in your family, genetic counseling before or early in pregnancy can clarify the options. For someone already diagnosed, contact the care team promptly about new or more frequent seizures, coughing or choking during feeds, fever with fast or labored breathing, or difficulty getting enough food and fluids. Ask the team for a written plan that says when a seizure or breathing trouble needs emergency care.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Sandhoff Disease is like, what's helped you, or ask the community a question.